In this open-label , phase @ trial , we randomly assigned @ patients with metastatic melanoma with a BRAF V@ mutation to receive either a combination of dabrafenib ( @ mg twice daily ) and trametinib ( @ mg once daily ) or vemurafenib ( @ mg twice daily ) orally as first-line therapy .